Nipocalimab (AChR-positive gMG) Expand Company: Janssen Clinical trial(s): Vivacity (Stage 2 complete) More information NICE status: Awaiting development (topic selected 3/1/24) MHRA status: Approved Nipocalimab is a FcRn inhibitor, similar to how efgartigimod and rozanolixizumab work. It has already shown clinical effectiveness in treating four other autoantibody-driven diseases, such as rheumatoid arthritis.
Pozelimab & Cendisiran (AChR-positive gMG and LRP4R-positive gMG) Expand Company: Regeneron Clinical trial(s): NIMBLE (estimated to complete 23/3/28) link to trial Recruiting in UK sites: Birmingham and Sheffield NICE status: No appraisal status at present time MHRA status: Not approved at present time · Pozelimab and Cendisiran are both complement inhibitors and work similarly to zilucoplan, eculizumab, and ravulizumab. There are being used as a combinatorial therapy to treat myasthenia gravis.
B Cell Inhibitors Expand Inebilizumab (AChR-positive gMG or MuSKR-positive gMG) · Company: Amgen · Trial: MINT (Phase 3, estimated completion 29/11/27, no UK trial sites) Mezagitamab (AChR-positive gMG or MuSKR-positive gMG) · Company: Takeda · Trial: Phase 2, completed 12/7/22 Satralizumab (AChR-positive gMG or MuSKR-positive gMG or LRP4R-positive gMG) · Company: Roche · Trial: LUMINESCE (Phase 3, estimated completion 2/9/24, no UK trial sites) Telitacicept (AChR-positive gMG or MuSKR-positive gMG) · Company: RemeGen Co · Trial: RemeMG (Phase 3, estimated completion 7/2027, not yet recruiting)
ARGX-119 (Congenital Myasthenic Syndromes) Expand Company: Argenx Clinical trial(s): Phase 1b completed, Argenx have announced plans to advance the clinical development of this medicine.
Cladribine (AChR, MuSK, LRP4, and Seronegative Antibody-Positive MG) Expand Company: Merck Clinical Trial: MyClad (Phase 3) more information Recruiting UK Sites: Sheffield and Nottingham NICE Status: Pending Cladribine is a B and T cell inhibitor that works to specifically target these immune cells.
Zilucoplan (Zilbrysq) (AChR-positive gMG) Expand Company: UCB Clinical trial(s): RAISE (Stage 3 complete) More information NICE status: Negative final draft guidance published after three committee meetings, myaware have appealed this decision, and the appeal has been upheld. We are now awaiting instructions from NICE regarding the fourth committee meeting. MHRA status: Approved Learn more about Zilucoplan.
Rozanolixizumab (Rystiggo) (AChR-positive and MuSKR-positive gMG) Expand Company: UCB Clinical trial(s): MycarinG (Stage 3 complete) More Information NICE status: Negative draft guidance published after first committee meeting, second and third committee meetings have now taken place (Q4 2025), and we are awaiting the outcome of these. MHRA status: Approved Learn more about rozanolixizumab.
Efgartigimod (Vyvgart) (AChR-positive gMG) Expand Company: Argenx Clinical trial(s): ADAPT (Stage 3 complete) More information and a paediatric study (actively recruiting) in Oxford. NICE status: Negative Final Guidance published in June 2025 after an appeal from Argenx and myaware. MHRA status: Approved Learn more about Efgartigimod.
IMVT-1402 Expand Company: Immunovant Sciences GmbH (Responsible Party) Clinical Trial: Phase 3 Recruiting Sites: Glasgow
Iptacopan Expand Company: Novartis Clinical Trial: Phase 3 Recruiting Sites: London, Southampton, Inverness, Swinton, Birmingham
T Cell Therapy (Myasthenia gravis) Expand Descartes-08 Company: Cartesian Therapeutics Trial: Phase 2b (estimated completion 31/3/26, no UK trial sites) YTB323 Company: Novartis Pharmaceuticals Trial: Phase 1/2 Recruiting sites: London and Sheffield CC-97540 Company: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company (Responsible Party) Trial: Breakfree-2, phase 1 Recruiting sites: London (Barts), London (UCL), Manchester Royal Infirmary, Salford Royal Hospital Povetacicept Company: Vertex Trial: Coming in the first half of 2026 for myasthenia gravis